Infectious Bursal Disease Vaccine Market
Report ID: SQMIG35H2425
Report ID: SQMIG35H2425
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2425 |
Region:
Global |
Published Date: February, 2026
Pages:
157
|Tables:
88
|Figures:
76
Global Infectious Bursal Disease Vaccine Market size was valued at USD 290.00 Million in 2024 and is poised to grow from USD 313.49 Million in 2025 to USD 584.56 Million by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).
The infectious bursal disease vaccine industry is on the verge of significant growth, with two drivers at the forefront driving this expansion, an expanded global poultry industry and a critical need to prevent the transmission of highly contagious viral infections which lead to millions of dollars in losses for poultry producers every year. The increasing number of infectious bursal disease outbreaks in the poultry industry combined with improved awareness for both animal and food safety have allowed for a greater use of both conventional live attenuated infectious bursal disease vaccines and newer formulations such as recombinant vaccines and inactivated vaccines, as they provide much wider ranges of protection as well as more safety.
In addition to government programs, the implementation of stricter biosecurity regulations and increasing amounts of capital investment into the veterinary infrastructure, many factors are supporting increased adoption of vaccines in commercial and backyard poultry. New technologies used in the production of vaccines including recombinant DNA technology, novel adjuvants and new cold chain distribution systems are increasing both the effectiveness and availability of vaccines in rural parts of the world.
Industry trends, like digital tracking of disease management using combination vaccines, are also changing how manufacturers consider their competitive positions within this market. As this industry matures and technology improves, the overall method of providing poultry producers with vaccines is likely to continue to improve, resulting in lower costs and greater efficiency for producers. Overall, there are multiple factors supporting the growth of the livestock infectious bursal disease vaccine market.
How is AI Improving Demand Forecasting in the Infectious Bursal Disease Vaccine Market?
Demand forecasting in the infectious bursal disease vaccine market is being improved through AI by integrating supply chain data, farm-level signals and external indicators to create timely and precise demand insights. Important factors include machine learning modelling where strains and their patterns, seasonality, etc., can be learned; natural language processing enables the extraction of outbreak reports; and real-time data integration from chick hatcheries and distributors. Current forecasting methods are evolving from a static historical format to an adaptive system that reduces the amount of waste, aligns production with regional risk, and enables manufacturers and poultry producers to more effectively coordinate vaccination schedules and inventories.
Market snapshot - 2026-2033
Global Market Size
USD 290.0 Million
Largest Segment
Live Attenuated Vaccine
Fastest Growth
Inactivated Vaccine
Growth Rate
8.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
The infectious bursal disease vaccine market is segmented into vaccine type, administration route, end user and region. Based on vaccine type, the market is segmented into live attenuated vaccine and inactivated vaccine. based on administration route, the market is segmented into injectable and oral. Based on end user, the market is segmented into poultry farms, research institutions and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per infectious bursal disease vaccine market outlook, live attenuated segment dominates because longstanding clinical effectiveness and broad immune stimulation make it the preferred choice for flock protection, driving manufacturer focus and veterinarian recommendations. In duration of immunity with a single dose schedule, the reduction in operational complexity and costs associated with disease management encourages a sustained level of uptake and investment by the manufacturer in production capacity. An established safety profile and use in routine vaccinations to establish their market leadership based upon consistent demand and commitment to the maintenance of supply chain agreements.
As per infectious bursal disease vaccine market forecast, inactivated vaccines segment is the fastest growing in the market due to improvements or advancements in antigen formulations and the improved safety of adjuvants for the vaccination of younger animals. The inactivated vaccine offers opportunities for combination products and for their use in conjunction with maternal antibodies therefore regulatory support and collaborative commercialization opportunities are increasing and have created much larger product development pipelines and new distribution opportunities which will drive future growth within the vaccine market.
As per infectious bursal disease vaccine market analysis, the injectable segment is dominant due to the ability to provide precise dosages and the number of established protocols for delivery by veterinarians leading to consistent immune responses over many types of poultry. Veterinarians prefer to use injectable vaccines for their targeted immunization campaigns; therefore, the controlled method of delivery decreases the amount of variability in terms of vaccine uptake and thus enhances the predictability of the health of the flock. This predictability affects manufacturer's focus on developing injectable vaccines. Additionally, the current training infrastructure and supply chains created around injectable vaccines have solidified this route in many commercial vaccination programs as the normal method in which vaccines are administered.
On the other hand, oral administration is experiencing very rapid growth as a result of the increasing popularity of mass delivery systems. This will allow for an entire flock to receive an immunization without having to be handled individually and will therefore eliminate much labor associated with individual bird handling. There have also been total improvements in both the stability of the formulation and the delivery vehicles such as water or feed, which will help to increase the use of oral delivery. This has encouraged producers to implement scalable vaccination programs that generate new opportunities for the manufacturers of vaccine manufacturers and their customers.
To get detailed segments analysis, Request a Free Sample Report
As per infectious bursal disease vaccine market regional outlook, Asia-Pacific Region leads by combining structural and operational strengths that promote the development, manufacture, and distribution of vaccines. Significant volumes of commercial poultry combined with repeated disease outbreaks drive the need for preventative solutions. Manufacturers located in the region have a focus on large-scale, cost-effective vaccine production. Regulatory bodies within the region are working collaboratively with both public and private sectors to facilitate accelerated approval and distribution of modified vaccine formulations.
Japan Infectious Bursal Disease Vaccine Market
The Japan market is characterized by strict adherence to quality standards and progressive vaccination technology because of collaborative efforts between public and private veterinary sectors. Capacity for research development and close working relationships between poultry producers and manufacturers facilitate the development of unique immunization strategies. Regulatory clarification and a focus on biosecurity enhance the implementation of quality vaccine formulations and the development of cold storage systems and testing equipment provide locations where they can mobilize quickly and easily and support the continued demand for quality vaccine products.
South Korea Infectious Bursal Disease Vaccine Market
The South Korean market for the infectious bursal disease (IBD) vaccine benefits from an evolving biotechnology sector and manufacturing capacity, which leads to rapid commercialization of vaccine research. The relationship between poultry producers and vaccine producers supports the establishment of insertion schedules and vaccine supply.
As per infectious bursal disease vaccine industry analysis, the rapid growth occurring within North America can be attributed to the combined effects of consolidation across multiple industries, increased use of technology, and a strong emphasis put on the health of flocks through veterinary services. There are integrated poultry operations with disease management programs that promote expanded use of vaccines on a consistent basis. The large animal health companies and local producers are advancing the development and delivery of new, more effective vaccines as well as the methods used to deliver these vaccines.
U.S. Infectious Bursal Disease Vaccine Market
The infectious bursal disease vaccine market in the United States is defined by the existence of integrated commercial poultry systems where proper vaccination strategies and proper veterinary supervision are key to success. There exist several companies that have been successful in developing and distributing both new and improved forms of vaccines for use in poultry. The large number of diagnostic laboratories and the services provided by those laboratories allow for a rapid response to any disease emergency and the development of targeted vaccination programs to respond to the disease emergency.
Canada Infectious Bursal Disease Vaccine Market
The infectious bursal disease vaccine market in Canada is characterized by a dispersed production model, because of which Canadian poultry producers need to implement adaptable immunization strategies supported by strong veterinary services. By working together, domestic vaccine manufacturers and research institutions are developing new and improved vaccines that are suited for combating viral challenges faced in different regions. The application of good biosecurity and traceability processes and outreach to poultry producers are critical components of aligning vaccination programs to on-farm practices.
Through joint regulatory harmonization, collective scientific expertise and investment in next generation vaccines that address differing viral strains in the region Europe is creating global competitive advantage. Additionally, strong collaboration between universities, contract manufacturers and leading animal health companies is providing an efficient mechanism for developing differentiated products and expediting their market entry through streamlined access to the approved product. Europe is also working collaboratively to ensure animal welfare and quality standards are tightly linked, which provide the basis for creating a demand for safe and effective products, as well as developing integrated veterinarian networks and diagnostic capacities that facilitate evidence-based immunization programs. Distribution channels across borders, and an export-oriented approach, will provide a scale for manufacturers.
Germany Infectious Bursal Disease Vaccine Market
Germany has a strong foundation in biotechnology and the manufacturing industry for creating high-quality vaccine formulations and delivery systems, as well as working closely together with research institutions, manufacturers, and veterinary companies to improve each vaccine’s functionality and to ensure they are prepared for regulation.
U.K. Infectious Bursal Disease Vaccine Market
As per infectious bursal disease vaccine market regional forecast, United Kingdom has many top-tier research facilities that are partnering with the industry to create new and innovative platforms and delivery methods for vaccines. By establishing veterinary networks for advice and using trial facilities, they will be able to provide more effective ways of determining how to implement the protocols associated with using vaccines. Their emphasis on animal welfare and the regulatory systems they have implemented will also give consumers confidence that the products they receive are safe. Furthermore, the UK has an export orientation and manufacturing capabilities that will allow vaccine producers to reach their international market easily and provide customized solutions based on their needs.
France Infectious Bursal Disease Vaccine Market
In France, the infectious bursal disease vaccine market has a robust research component and strong biotechnology industry that has allowed them to develop vaccines that are specific to the regional nature of the pathogens associated with the disease. Manufacturers and laboratories as well as producer representatives work together to achieve tailored immunization strategies and validation processes. Regulatory compatibility with other regions of the European Union as well as the emphasis on providing consumers with a safe product gives the France market confidence in their vaccine supply. In addition, France has a well-established distribution system for vaccines that will help give all commercial producers access to the vaccine and improve the overall output of the vaccination supply within the country.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Demand for Poultry Products
Advances In Vaccine Technology
Cold Chain Distribution Challenges
Regulatory Approval Complexity
Request Free Customization of this report to help us to meet your business objectives.
The current competitive environment of the global infectious bursal disease vaccine market will be influenced by the introduction of new products into the market, consolidation of existing products as well as some specific targeted biotechnology (biotech) disbursements which provide a shift in capability towards new platforms and approaches for manufacturing vaccines. Manufacturers are focused on new vaccines that will be launched in three different vector/trivalent combinations, pursuing strategic alliances with companies making niche innovative products.
While they will be acquiring these niche players to diversify their product pipelines as evidenced by the launch of VAXXITEK HVT plus IBD by Boehringer Ingelheim; the introduction of Poulvac Procerta by Zoetis; and the spin-off of BiomEdit, along with mid-size animal health companies’ recent acquisition activities.
Recombinant and Novel Platforms
Precision Vaccination and Farm Integration
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the infectious bursal disease vaccine market is driven by the growing global poultry industry along with the increase in risk of disease and demand for vaccines. However, the availability of vaccines in rural areas is constrained by the cold chain distribution system. The region with the largest commercial poultry flocks and vaccine manufacturers is Asia Pacific, and live attenuated vaccines are the largest segment of the market, given their proven efficacy and ease of administration. Another driver of infectious bursal disease vaccine market growth is the rapid pace of innovation in technology that can convert pathogen detection and diagnosis into targeted recombinant and vector-based vaccine strategies.
These factors together promote concentration of the manufacturers and the development of region-specific vaccine portfolios. The market is moderately consolidated, with leading veterinary pharmaceutical companies accounting for a substantial infectious bursal disease vaccine market share through extensive product portfolios, strong distribution networks, and long-term partnerships with commercial poultry producers.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 290.00 Million |
| Market size value in 2033 | USD 584.56 Million |
| Growth Rate | 8.1% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Infectious Bursal Disease Vaccine Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Infectious Bursal Disease Vaccine Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Infectious Bursal Disease Vaccine Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Infectious Bursal Disease Vaccine Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Infectious Bursal Disease Vaccine Market size was valued at USD 290.0 Million in 2024 and is poised to grow from USD 313.49 Million in 2025 to USD 584.56 Million by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).
Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Cegelec, Hipra, Intervet, Vetoquinol, Virbac, Dechra Pharmaceuticals, Neovia, Bioveta, Axiota Animal Health, Biopharma, HyGentec, Liaoning Hile Biotechnology, Jinsha River Holdings, Chengdu Tiantai Technology, Indivior, Sihuan Pharmaceutical
The key driver of the Infectious Bursal Disease Vaccine Market is the rising prevalence of infectious bursal disease in poultry and the growing demand for effective vaccination programs. Increasing poultry production, along with the need to improve flock health and reduce economic losses, is further driving market growth.
A key market trend in the Infectious Bursal Disease Vaccine Market is the increasing adoption of recombinant and next-generation vaccines that provide improved safety and stronger immunity in poultry. Additionally, advancements in vaccine delivery methods and multivalent vaccines are enhancing disease prevention and vaccination efficiency.
Asia-Pacific accounted for the largest share in the Infectious Bursal Disease Vaccine Market, driven by high poultry production, increasing adoption of vaccination programs, rising awareness of poultry disease prevention, and growing demand for quality poultry meat and eggs.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
